To prevent major limb amputations in patients with critical limb ischemia and foot ulcer
Intramuscular injection,1 ml into the ischemic limb, along post and anterior tibia
(i) Improved (ii) Healed group improvement skin perfusion pressure, laser doppler perfusion pressure 5, and laser doppler perfusion pressure heat value in 90 days (iii) Corresponding toe pressure (increased from mmHg to mmHg) (iv) Brachial index increased from to mmHg (v) No significant difference in Transcapillary pressure of oxygen and neutrophil count (vi) Significant increase in C-reactive protein () in poorly healed limbs 30 days after treatment
Selecting the most preferable stem cells for the treatment of diabetic critical limb ischemia and foot ulcer
2 ml cells, injected in basal of foot ulcer and surrounding tissue
(i) Stem cells appeared to show better results with an ulcer healing () (ii) Limb perfusion (), ankle-brachial index () (iii) Magnetic resonance angiography analysis (), with no significant difference in pain relief and amputation rate
Access for safety, efficacy, and feasibility of cellular products in improving of microcirculation and lowering of amputation rates
Intramuscular injection in M. gastrocnemius ipsilateral 1 ml each in deep
(i) Improved (ii) BM-MSCs had an 83% ulcer healing rate, improved ankle-brachial index () compared with TRCs at 80% (iii) No significant difference in transcapillary pressure of carbon dioxide microcirculation improved in some patients in both groups
To determine the potential of allogeneic stem cell sheets for treating diabetic foot ulcers
Allogeneic stem cell sheet put direct on the wound bed
(i) Improved, complete wound closure faster. Rate of wound size reduction at one-week post cell application. Reduction rate % in the treatment group compared to % in control group (). Complete wound closure of 73% at 8 weeks with 47% observed in controls () (ii) Further improvement in complete wound closure at 12 weeks in the treatment group while control improved only by 53% in the same period () (iii) Outcomes of the Kaplan-Meier median times to complete closure were 28.5 days within the treatment group, while a delay of 63.0 days in the control group was prominent () (iv) The mean time required for complete closure was days in the treatment group and days in the control group. Antibodies were slightly elevated in 27% of patients without clinical signs at 12 weeks and in 20% of patients of the control group. There were no signs of rejection observed
To investigate safety and outcomes after intralesional allogeneic adipose-derived mesenchymal stem cell injection in chronic diabetic foot ulcers
Injected into the dermoepidermal junction and homogenously the whole of the wound
(i) Postadministration follow-up parameters for patients’ evaluation included demographics, wound characteristics, wound closure time, amputation rates, and clinical scores. Outcomes mean follow-up duration 48.0 (26-50) months, mean ulcer duration days, and lesion size (ii) Mean time to wound closure was , range 22-55days in AD-MSC group and days in control group, . Higher scores in of SF-36 physical functioning and general health domains () and higher costs in AD-MSC group compared to the control group at (iii) No adverse events were observed throughout follow ups in the bother study group. Wagner grade I:11 patients (55%) and Wagner grade II: 9 patients 45% (iv) Wound closure was achieved in 85% of lesions, 17/20 patients in the AD-MSC group
